Norway started vaccinations on December 27 and 1.1 million people – out of a population of 5.3 million – have been vaccinated so far.
YOU AIA: The EU drug watchdog said Friday that a review of AstraZenecaThe Covid-19 vaccine found that its benefits increase with age and continue to outweigh the risks for adults despite links to blood clots.
You European Medicines Agency (EMA) presented its results after the European Commission asked for concerns that have prompted several countries to restrict its use to older people to be examined.
“It has shown that the benefits of vaccination increase with increasing age and infection rates,” the Amsterdam-based EMA said in a statement.
“The benefits of Vaxzevria outweigh its risks in adults of all ages; however, there have been very rare cases of blood clots with low blood platelets after vaccination,” he said, using the AstraZeneca brand for the vaccine.
Public confidence in the AstraZeneca jab has taken a hit since the EMA declared on April 7 that a very rare, but often fatal, form of blood clot affecting the brain should be listed as a side effect.
The clots are also listed as a side effect of the J&J vaccine, which uses the same adenovirus vector technology as AstraZeneca, the EMA said earlier this week.